全球领先的新经济产业第三方数据挖掘与分析机构
关于“医药电商”的报告
-
-
艾媒咨询|2021年中国夜间用药年度观察报告
本报告涉及的案例/品牌/企业：美团买药，叮当快药
在众多社会服务中，夜间用药成为人们最关注的夜间社会服务之一，近年来，各地相关行政管理机构也陆续出台相关扶持政策，鼓励商家上线夜间送药平台、发展24小时药店，提供夜间送药服务，推动解决“夜间买药难”问题。近日，iiMedia Research(艾媒咨询)最新发布《2021年中国夜间用药年度观察报告》，基于2021年初至2021年末的监测数据，对中国夜间用药市场持续追踪。报告显示，年初有61.2%的用户夜间生病选择忍，而年底这一数字降至52.1%，据推算年末夜间用药受益群体新增约4000万人。报告指出，日渐成熟的中国外卖送药平台，成为解决夜间用药的重要参与者。通过一年的发展，在美团买药“小黄灯”计划等24小时药店惠民工程的推动下，线上24小时药店数量增加、夜间买药配送速度更快、服务保障更加成熟，用户知晓度有了较大提升，夜间买药难的问题得到有效缓解。
Among many social services，night medication has become one of the night social services that people pay most attention to. In recent years，relevant administrative agencies around the country have also successively issued relevant support policies to encourage businesses to launch night medication delivery platforms，develop 24-hour pharmacies，provide night medication delivery services， and promote the solution of the problem of "difficulty in buying drugs at night". Recently， iiMedia Research released the annual observation report on nighttime medication in China in 2021，which continuously tracks China's nighttime medication market based on the monitoring data from the beginning of 2021 to the end of 2021. The report shows that at the beginning of the year， 61.2% of users chose to tolerate illness at night，while at the end of the year，the figure fell to 52.1%. It is estimated that about 40 million people will benefit from night medication at the end of the year.The report points out that the increasingly mature Chinese takeout delivery platform has become an important participant in solving the problem of night medication. Through one year's development，driven by the 24-hour pharmacy benefit project such as the "small yellow light" plan of meituan drug purchase， the number of online 24-hour pharmacies has increased，the speed of drug purchase and distribution at night is faster，the service guarantee is more mature，the user awareness has been greatly improved，and the problem of difficult drug purchase at night has been effectively alleviated. -
艾媒咨询|2021年中国互联网医院行业发展研究报告
本报告涉及的案例/品牌/企业：医联，京东健康，好大夫
随着《健康中国2030规划纲要》、“互联网+医疗健康”的国家倡导和执行方针落实，中国互联网医院的数量在2015-2020年五年间增长近1000家，2021年进入稳定上升期。iMedia Research(艾媒咨询)数据显示，自2018年起，中国互联网医院行业进入以医院主导的互联网医院占多数的发展状态。医院主导和企业主导的互联网医院各有不同竞争优势，面对国家的规范政策和市场需求增长，通过差异化定位和院企合作能有效提升各方效益。
With the implementation of the national plan for health China 2030 and Internet plus medical health, the number of China's Internet hospitals increased by nearly 1000 in 2015-2020 years and five years, and entered a stable rise in 2021. According to the data of imedia research, since 2018, China's Internet hospital industry has entered a development state in which hospital led Internet hospitals account for the majority. Hospital led and enterprise led Internet hospitals have different competitive advantages. In the face of national normative policies and market demand growth, the benefits of all parties can be effectively improved through differentiated positioning and hospital enterprise cooperation. -
艾媒咨询|2021全球与中国医药电商市场与发展趋势研究报告
本报告研究涉及企业/品牌/案例：阿里健康，美团，京东健康，叮当快药，1药网，Walgreens，百度健康，药材买卖网，中药材天地网，找药网，九州通，药易购，珍诚医药在线，CVS
在政策利好、互联网技术等多重因素推动下，中国医药电商行业规模持续快速发展，2020年中国医药电商市场交易规模达到1956亿元。当前，中药电商商业模式主要为B2B、B2C、O2O与DTP四种类型，其中，2020年，医药电商B2C模式占比近6%，市场规模为116亿元；医药电商B2C模式占比近84%，市场规模为1640亿元，成为当前的主流。此外，近几年兴起的O2O模式，主要通过“引流-转化-消费-反馈”等实现盈利，而DTP药房模式下，患者在医院开取处方后，药房根据处方以患者或家属指定的时间和地点送药上门，被称为高值新特药直送平台。
Driven by favorable policies, Internet technology and other factors, the scale of China's pharmaceutical e-commerce industry continues to develop rapidly, with the transaction scale of China's pharmaceutical e-commerce market reaching 1956 billion yuan in 2020. At present, the business models of traditional Chinese medicine e-commerce are mainly B2B, B2C, o2o and DTP. In 2020, the B2C model of pharmaceutical e-commerce accounts for nearly 6% and the market scale is 11.6 billion yuan; the B2C model of pharmaceutical e-commerce accounts for nearly 84% and the market scale is 164 billion yuan, which has become the current mainstream. In addition, the o2o mode, which has sprung up in recent years, mainly achieves profits through "drainage transformation consumption feedback". In the DTP pharmacy mode, after patients get prescriptions in the hospital, the pharmacy delivers drugs to the door at the time and place designated by the patients or their families according to the prescriptions, which is known as the high value new special drugs direct delivery platform. -
艾媒咨询|2020-2021中国互联网医疗行业发展白皮书
本报告研究涉及企业/品牌/案例：科亚医疗,灵医智惠,京东健康,爱康体检宝
2021年中国移动医疗市场规模预计将达到635.5亿元，用户规模将扩大至6.87亿人。医疗器械设备与电商行业的发展，推动中国互联网医疗行业市场迎来新的发展机遇。首先是中国政策环境的利好，同时互联网医疗服务行业在2020年迎来重大普及发展的历史机遇，行业经济前景可观。医疗硬件设备的提升与专业数字化医疗网络的搭建同样为互联网医疗提供更长远技术支持。2019年中国移动医疗行业投资交易规模急剧增长至162亿元，资本市场密切关注中国移动医疗产业发展。iiMedia Research（艾媒咨询）数据显示，受访用户对于当前互联网医疗行业服务表示“比较认可”占比46.0%，“非常认可”占比22.2%。其中，在诊前、诊中以及诊后环节中，最受认可的因素分别为服务时间地点灵活、就诊过程快捷以及在线支付方便，互联网医疗在效率上的提升得到用户普遍认可。未来中国医疗器械将在产品功耗、专业性、安全性等方面有更高的要求，走向更具创新性、人性化、精细化将成必然。
In 2021, China's mobile medical market is expected to reach 63.55 billion yuan, and the number of users will expand to 687 million. The development of the medical equipment and e-commerce industry has promoted China's Internet medical industry market to usher in new development opportunities. First of all, China's favorable policy environment. The Internet medical service industry had a major historical opportunity for popularization and development in 2020, and therefore the industry's economic prospects are considerable. The improvement of medical hardware equipment and the construction of professional digital medical networks also provide longer-term technical support for Internet medical treatment. In 2019, the scale of investment transactions in China's mobile medical industry increased sharply to 16.2 billion yuan, and the capital market paid close attention to the development of China's mobile medical industry. According to data from iiMedia Research, 46.0% of the interviewed users expressed "relatively recognized" and "very recognized" accounted for 22.2% of the current Internet medical industry services. Among them, the most recognized factors in the pre-diagnosis, in-diagnosis, and post-diagnosis links are flexible service time and location, fast medical treatment process, and convenient online payment. The efficiency improvement of Internet medical treatment is generally recognized by users. In the future, China's medical equipment will have higher requirements in terms of product power consumption, professionalism, and safety, and it will be inevitable to move toward more innovative, humane, and refined products. -
艾媒咨询|2020年中国互联网医疗行业发展专题研究报告
本报告研究涉及企业/品牌/案例：圆心科技集团，圆心医疗科技，圆心惠保，阿里健康，浙一互联网医院，丁香园。
近年来，中国互联网医疗行业发展迅速，从萌芽期步入到高速发展期。2020年，互联网医疗受新冠疫情影响发展继续加快，5G和人工智能技术逐步落地应用也助推行业规模增长。iiMedia Research（艾媒咨询）数据显示，74.4%的受访网民在疫情期间参与过互联网医疗服务，且认为其能够减轻门诊压力和避免交叉感染的网民占比也超过七成。在互联网医疗主要细分市场中，移动医疗平台借助移动互联网普及和物流水平提高，其品牌认知和市场发展较快，2020年中国移动医疗用户规模将达到6.35亿人，市场规模也将超过520亿元。
In recent years, China Internet medical industry has developed rapidly, from the embryonic stage to high-speed development period. In 2020, the development of Internet medical industry will continue to accelerate under the influence of Covid-19, and the application of 5G and AI technology will also boost the growth of the industry scale. As the data of iiMedia Research showed, 74.4% of the interviewed netizens participated in Internet medical services during the Covid-19 period, and more than 70% netizens believed that it could reduce the pressure of outpatient service and avoid cross infection. In the main market segments of Internet medical industry, mobile medical platforms, with the help of the popularization of mobile Internet and improvement of logistics level, have a rapid brand recognition and market development. In 2020, the user scale of China mobile medical industry will reach 635 million, and the market size will also exceed 52 billion yuan. -
艾媒报告|2020-2021年中国医疗电商行业发展趋势及标杆企业分析报告
本报告研究涉及企业/品牌/案例：平安好医生,康爱多,阿里健康,健客,鱼跃医疗；其他提及企业/品牌：益药购,1药网,九州通网,心诺,我的医药网,好药师,美之氧,药京采,七乐康,欧姆龙,普天药城网,氧生活,未名企鹅,爱康多,巨人,药药好,京东大药房,康祝,药品终端网,360好药,可孚,药师帮,药房网,艾润科技,药便宜,八百方
2020年3月9日，全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020-2021年中国医疗电商行业发展趋势及标杆企业分析报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据，对2020年中国医疗电商产业发展进行分析。本报告主要通过医药电商和家用医疗器械两方面，对医疗电商产业上下游深入探究运行模式，并对鱼跃集团、平安好医生、爱康多等典型企业进行案例分析，以此对中国医疗电商行业发展进行趋势预判。2019年中国医药电商行业发展规模继续增大，涌现出许多新型零售方式。越来越多医药企业涌入B2B主流市场，B2C市场规模也随着消费者健康意识的提升以及网购消费习惯的固定而得到较大发展；越来越多药企也开始开展O2O业务。以药到医、“医+药”发展的模式也受到普遍认可。特别在新型冠状病毒肺炎疫情影响下，医疗电商以其独特的互联网优势在抗击疫情中发挥了重要作用。在此契机下，医疗电商行业将在2020年迎来重大普及发展的历史机遇期。
In 2019, the scale of China's pharmaceutical e-commerce industry continues to increase, and many new retail methods have emerged. More and more pharmaceutical companies have entered the mainstream B2B market, and the scale of the B2C market has also grown significantly with the improvement of consumers' health awareness and the fixation of online shopping consumption habits; more and more pharmaceutical companies have begun to develop O2O business. The development model from medicine to medicine and "medicine + medicine" has also been widely recognized. Especially under the influence of the new coronavirus pneumonia epidemic, medical e-commerce has played an important role in fighting the epidemic with its unique Internet advantage. With this opportunity, the medical e-commerce industry will usher in a period of historical opportunities for significant popularization in 2020. -
艾媒报告 |2019全球与中国医药电商市场与发展趋势研究报告
本报告研究涉及企业/品牌/案例：天猫医馆，七乐康，京卫大药房，阿里健康大药房,京东大药房,健客, 1药网,360好药,八百方,818医药网,CVS,Walgreens ,RiteAid ,开心人网上药店，药房网，药材买卖网，珍材网，中药材天地网，商康网，科欣医药，医药在线，我的医药网，药品交易网，药品终端网，药师帮，海王晨星，快方送药，药给力，搜药送，药急送，U医U药，叮当送药，健客网上药店，康爱多掌上药店，问药，好药师，111集团，中宏保险，医联，腾讯，仁和药业，浙江扁鹊，漱玉平民，华人健康，一树药业，德生堂
2019中国医药电商主要形成了B2C、B2B、O2O三种模式，B2C模式体量稳定在6%左右，规模呈增长趋势，预计2019年的市场交易额将达到554.6亿元;B2B模式下，西药类产品的需求比例较高，达87.1%，中药材、传统药品和第三方交易等都形成了专属B2B平台;而近几年兴起的O2O模式，主要通过“引流-转化-消费-反馈”等实现盈利，但区域覆盖度和消费者的信任度需要提高。iiMedia Research(艾媒咨询)大数据监测显示，目前1药网、健客网上药店、康爱多掌上药店的的综合实力排行较强。
2019 China's pharmaceutical e-commerce mainly formed three modes of B2C, B2B and O2O. The volume of B2C model is stable at around 6%, and the scale is increasing. It is expected that the market transaction volume in 2019 will reach 55.46 billion yuan; in B2B mode, western medicine The demand ratio of products is relatively high, reaching 87.1%. Chinese herbal medicines, traditional medicines and third-party transactions have formed a proprietary B2B platform. In recent years, the O2O model has emerged mainly through “drainage-conversion-consumption-feedback”. Achieve profitability, but regional coverage and consumer trust need to be improved. iiMedia Research (Ai Media Consulting) big data monitoring shows that the current comprehensive strength of 1 drug network, Jianke online pharmacy, Kang Aiduo pharmacy is strong.
